Catalyst Hunting: The Actinogen Story (ASX: ACW)

Good morning Armchair Army,

Welcome to today's edition of The Armchair Analyst, a 5-minute daily update on the ASX life-sciences sector.

Early-stage drug developers don't make money.

They spend money.

Working along a 10 to 15-year journey to get a drug approved in the market.

… and then they make a whole bunch of money at once when the drug is approved.

(including milestone payments from partners OR royalties on drug sales).

Along that 10 to 15-year journey, there are many inflection points that de-risk the investment as it moves from one stage to another.

There are two main things that move the markets in biotech land.

Deals and data.

Generally, it's data FIRST, then deals AFTER.

Phase 1 (safety)...

Phase 2 (efficacy, small trial)...

Phase 3 (large registrational trial)...

The further along the phase, the more de-risked the science and the closer the company is to bringing a drug to market.

(or landing a licencing deal)

For the Armchair Scientists, we can evaluate if the scientific theory makes sense…

But without solid data, we're essentially shooting in the dark.

That's why clinical trial readouts are the most important de-risking factor for any biotech company.

Hit a primary endpoint… and the company has moved up to the next level.

Miss, and it's a big step backwards.

That is why these readouts are such binary events, and why companies spend tens of millions of dollars to get answers to those two questions.

Is my drug safe?

Does my drug work?

A trial result is the purest form of a known unknown.

This is how I normally see it play out…

As the result approaches, interest builds, speculation creeps in, and new investors enter the stock hoping to be positioned ahead of a positive outcome.

ALSO, existing holders are less inclined to sell because they want exposure to the result.

With fewer sellers and more buyers, prices rise, sometimes quickly.

The trick with these catalyst bets is to identify the companies BEFORE the run-up to a result.

BUT how Risk ON or Risk OFF the market is at a certain time will dictate how hard and fast the share price rises in anticipation of a binary trial result.

(If at all)

I like to look at these catalysts generally six months before they are set to land.

The next company on my Biotech 165 Challenge is now in the sweet spot.

Actinogen (ASX: ACW), six months away from a Phase 2b/3 result for Alzheimer's.

A potential "company-making" catalyst.

But first…The Pulse Check

Actinogen (ASX: ACW) is developing Xanamem, an oral, once-a-day pill that lowers cortisol inside the brain to try to slow the progression of Alzheimer's disease.

We are six months out from the company's catalyst.

It's cashed up… and has recruited its last patient.

We know the trial result timeline… It's all a waiting game now.

So, how do I like to play these catalysts?

This is a strategy I learned working at my old firm, Next Investors…

Identify a catalyst early.

Invest when interest is low.

Top-slice the investment in the lead-up to the results as speculators enter.

And hold a decent portion through the result.

The results of Actinogen’s trial are expected in November 2026.

The company recently raised $16.8 million at $0.042 per share, following a positive interim trial result in January.

The stock has been churning through that raise, and over the last couple of weeks has fallen victim to the tax-loss selling.

I'd expect interest in the result to start picking up about 6 to 8 weeks beforehand.

… but let's see if that interest turns to share price action.

Whether the market is risk-on or risk-off will depend on the outcomes of several other trials set to land before then.

Actinogen doesn't trade in a vacuum.

The overall mood of the small-cap biotech sector will determine whether money flows into the sector during the run-up.

And there are three readouts landing BEFORE Actinogen's that will tell us a lot about that mood.

Trial result: Phase 3 interim (CBD for insomnia)

Scheduled: ~6 weeks (late June 2026)

Armchair Take: The Avecho share price began moving about 12 months ago, off a base of around 0.4 cents, after the company completed a capital raise to fund it through to the interim analysis.

It's up roughly 200% over the year.

A perfect example of a catalyst trade: identify it early, get positioned before the crowd, and let the run-up do the work.

Full Article: Don’t sleep on this one: The Avecho (ASX: AVE) Story 

Trial result: Phase 2 (graft-versus-host) AND Phase 3 (knee osteoarthritis) results

Scheduled: June / early July 2026

Armchair Take: Cynata's share price also started moving about 12 months ago.

15 cents in June last year was the nadir.

It ran to a high of 40 cents in early January as the company announced recruitment was complete for BOTH of its clinical trials.

Some heat has since come out of the stock; it's pulled back from that high to around 26 cents, which suggests the market is currently in risk-off mode.

Cynata is currently in suspension due to the results.

Full article: Playing the Catalysts: The Cynata Story (ASX: CYP)

Trial result: Phase 3 interim analysis (injectable pentosan polysulfate for knee osteoarthritis)

Scheduled: Mid-2026

Armchair Take: Avecho and Cynata were textbook. 

Bottomed about a year out, then ran into their catalysts as the date got closer.

Paradigm has a catalyst of the same calibre landing mid-year, the interim analysis of its global Phase 3 in knee osteoarthritis.

But it hasn’t run.

This is a capital structure issue, not a catalyst issue.

Paradigm went into this period needing money. A classic come-raise.

In July 2025, it signed a US$27 million convertible note facility with Obsidian Global Partners and started drawing it down.

Then, in April 2026, it tapped the market again with a $21 million placement that included an SPP, partly to repay that note and "reduce reliance on future drawdowns."

A convertible note on the register is an overhang.

So the squeeze you'd normally get, a tightly held minnow grinding higher into a binary event… hasn’t shown up. 

Yet...

There are still a few months to go… let’s see how it plays out.

Actinogen had its own version of the “run up to catalyst” late last year.

The company published the interim results for this Phase 2b/3 study, which had two possible outcomes.

Go or No Go.

The result was a Go, and the company made the call to raise capital off the back of this (without necessarily letting the stock trade on the result).

Sensible. 

It raised $16.8 million at 4.2 cents per share, off the back of the good news, extending its cash runway through mid-2027.

It DID snuff some of the momentum (raises usually do).

But it also means Actinogen is now fully funded to its November readout; no come-raise hanging over it.

I expect the attention to return as we get closer.

The challenge is that the full euphoric run-up hasn't quite happened yet for the biotech sector.

It all depends on whether the market is Risk On or Risk Off.

The more winners the market sees…

… the more Risk On the market gets.

And the more Risk On it gets, the harder these stocks run into their catalysts.

Two big-profile failures have made the sector cautious.

There was Opthea (ASX: OPT), which had two Phase 3 trials running at once in wet macular degeneration and a market cap north of A$1 billion.

The trial failed, and the company only returned to the market after a year of suspension.

97% down on return.

And there was Immutep (ASX: IMM).

Immutep was trading at around 40 cents in March, with a credible Phase 3 lung cancer program in partnership with Merck.

Then its futility analysis came back: the drug arm was actually underperforming the control arm.

The stock crashed by over 90% in a single session and went back to cash backing.

Two collapses like that, and you can see why money has been slow to step into the next round of catalyst bets.

So, will we get a run-up to the Actinogen result?

I think a lot depends on what lands before it.

If Avecho, Cynata and Paradigm get good readouts…

Then I think there should be buoyant sentiment across the sector.

And a buoyant sector is exactly the backdrop you want heading into a catalyst.

Right. Cortisol time.

You know cortisol as the stress hormone.

The thing that spikes when you're late for a flight or your kid draws on the wall.

That's blood cortisol.

But there's a second system.

Inside your cells sits an enzyme called 11β-HSD1 that acts like a little cortisol factory: it converts inactive cortisone back into active cortisol right there inside the cell.

Picture a big house with central heating set to a perfectly normal temperature.

That's your blood cortisol; it looks fine on the main dial.

But one room has its own space heater cranked to max.

That's 11β-HSD1 inside the brain cell.

Stand in the hallway with a thermometer, and everything reads comfortable.

Walk into THAT room with the space heater, and you're roasting.

The rooms that run hottest are the hippocampus and frontal cortex.

Exactly the regions Alzheimer's chews up first.

The "cortisol hypothesis" of Alzheimer's says chronically high cortisol inside those brain cells slowly poisons them, shrinking the hippocampus, killing neurons, and accelerating decline.

Actinogen’s drug is a small molecule that crosses the blood-brain barrier and blocks 11β-HSD1.

We can see this in a PET scan study conducted by Actinogen, which shows its drug binding to the target enzyme throughout the brain.

(absence of colour shows its binding)

By blocking this enzyme, Actinogen is unplugging the space heater.

The idea is that this lowers cortisol levels inside brain cells without affecting the adrenal glands or your blood cortisol (the central heating).

That's the theory anyway.

This is actually not Actinogen's first attempt to demonstrate efficacy in a clinical trial.

The first time around, in 2019, the company didn't meet its efficacy endpoints in its much shorter Phase 2a study.

That's normally a tough spot for an early-stage biotech.

But Actinogen went back through the data, analysed newly available blood biomarkers, and found a signal.

A signal is a piece of information or a trend that suggests a potential link between an intervention and an effect.

Specifically, it found that patients with elevated blood pTau-181 had a benefit.

A subgroup.

pTau-181 is a biomarker; evidence that you genuinely have progressing Alzheimer's.

For patients without the biomarker, the drug didn't move the needle.

(Which makes sense; you can't slow a disease in someone who doesn't really have it.)

Noting that this is a post hoc finding in a small subgroup of 34 people. 

The kind of thing you treat as a hypothesis, not a victory.

But Actinogen did the right thing.

It redesigned the next trial to enrol ONLY pTau-181-confirmed patients; the ones the drug should actually help.

And the early read on that bet is encouraging.

The trial has already passed its interim futility analysis.

An independent committee reviewed the unblinded data and said: "There's enough here to keep going without amendment."

It is no guarantee the drug works.

But it's a meaningful, directional move toward the endpoint.

For thirty years, the entire Alzheimer's field bet on one idea: amyloid.

The theory says sticky amyloid-beta plaques kick off the disease, so clear the plaques and you slow it down.

This is the foundation for the only two disease-modifying drugs currently approved: lecanemab (Leqembi) and donanemab (Kisunla).

But two things have shaken confidence in the amyloid-only story.

First, the science underneath it took a credibility hit.

A run of data-integrity failures rocked the field; most notably, the June 2024 retraction of the landmark 2006 Nature paper that helped anchor the amyloid hypothesis.

AND a separate NIH research-misconduct finding in 2024 against the neuroscientist who ran its neuroscience division.

Second, even where the drugs work, the benefit is modest.

A major Cochrane review in April 2026, pooling 17 trials and over 20,000 patients, concluded the average effect on cognition was "absent or trivial," and well below the threshold most clinicians consider clinically meaningful.

It's not my place to tell you whether FDA-approved drugs are good or bad.

But it does highlight the gap in the space.

And the industry has moved in this direction.

Amyloid's share of the Alzheimer's pipeline has roughly halved over the past decade, while tau and inflammation approaches have surged.

Money is fanning out beyond amyloid.

Even the giants are taking swings.

In November last year, Novo Nordisk's huge trial of semaglutide (yep, the Ozempic molecule) for Alzheimer's came back with no cognitive benefit.

Three days earlier, J&J's anti-tau antibody had flopped in its mid-stage trial too.

The scientific world is scratching around for the answers… and nothing yet has been found.

IF Actinogen has a good result (and it’s a big IF, since the initial trial only showed a post hoc signal), THEN I think it would be a genuine game-changer for the industry.

Amyloid only buys a modest slowdown. It’s clear something else is driving this disease.

Inflammation?

Tau?

Metabolism?

Cortisol?

We’ll find out in November if Actinogen has the answer…

Both the FDA and the EMA have told Actinogen the same thing…

A good result here, and the company is just one more Phase 3 trial away from registration.

We're in the sweet spot I like for these catalysts.

Six months out.

Cashed up.

Last patient in.

Whether the stock runs before the result depends on how comfortable the market is with risk.

The more risk on, the more likely a run into the trial.

The more risk off, the more of a struggle.

It's a binary bet, with all the risk that word carries.

But it's a binary bet, with the upside being a genuinely industry-shaping piece of information in an incredibly hard-to-treat disease.

A big thank you to Actinogen's CFO, Will Souter, and CEO, Steven Gourlay, for sharing the story with me.

See you all tomorrow,

The Armchair Analyst.

Dimerix (ASX: DXB) licenses DMX-200 to Everest Medicines for commercialisation in Greater China, South Korea, and Southeast Asia. US$10M upfront and US$330 million in potential milestones. (DXB)

🪑 Huge. Well done to the Dimerix team.

Memphasys (ASX: MEM) has executed a 12-month exclusive national supply agreement with Monash IVF for its Felix™ system and is entering a trading halt to facilitate a capital raise. (MEM)

🪑 Another very good deal.

Interesting choice to raise capital off the back of it. Hopefully, it's a big raise that can clear out the convertible note.

Good luck!

Cynata Therapeutics (ASX: CYP) initiates voluntary suspension pending results from Phase 3 Osteoarthritis and Phase 2 Graft versus Host Disease. (CYP)

🪑  Getting lots of texts on this one this morning. Hold firm, probably still waiting on those results for aGvHD.

This was from the placement announcement:

So should be any day now…

Nyrada Inc (ASX: NYR) provides a trial update on its Phase 2a study. Specifically, it has made some logistical changes to accelerate patient recruitment. Study still on track for end CY2027. (NYR)

🪑  Reading between the lines, it appears that recruitment is slower than anticipated (mainly due to ‘screen out’ requirements). 

Each new potential patient is one who will come in with a stroke. That patient has to meet the age criteria and come to the hospital at the right time (during operating hours).

But 20 patients have been screened; no patients have been recruited yet.

Still ‘on track’ to complete the study at the end of CY2027.

Eve Health Group (ASX: EVE) initiates a pilot pharmacokinetic study for its oral soluble film for erectile dysfunction. (EVE)

Clinuvel Pharmaceuticals (ASX: CUV) files Form 20-F with the US SEC, its next step towards an upgrade towards a NASDAQ ADS listing. (CUV)

BlinkLab (ASX: BB1) partners with ESPOCH on a large-scale autism study in Ecuador, using its smartphone-based technology. (BB1)

🪑 First Morocco, now Ecuador.

Some interesting jurisdictions to partner with and collect data from. But it does show that autism detection is a global challenge.

Micro-X (ASX: MX1) has secured a research partnership with the University of Sydney to evaluate its technology for future miniaturised lung CT applications. Funded by a $1.9 million grant from the Australian Government’s CTC program. (MX1)

🪑 Nice update.